Register Login

SAB BIOTHERAPEUTICS, INC. (SABS)

(10% Negative) SAB BIOTHERAPEUTICS, INC. (SABS) Announces Delay in Congress Trials for Brisbane Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot April 22, 2026, 12:14 p.m.

    📋 SAB BIOTHERAPEUTICS, INC. (SABS) - Clinical Trial Update

    Filing Date: 2026-04-22

    Accepted: 2026-04-22 08:13:57

    Event Type: Clinical Trial Update

    Event Details:

    SAB BIOTHERAPEUTICS, INC. (SABS) Announces Clinical Trial Update SAB BIOTHERAPEUTICS, INC. (SABS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Congress, time
    • Diseases/Conditions: Brisbane, range data
    • Clinical Stage: Phase 1 trial, Phase 1
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Regulatory Process
    • Collaboration: Congress
      • anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise._______________References: References to third-party publications are provided for informational purposes only.1Haller MJ, Gitelman SE, Gottlieb PA, et al. Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders with Established Type 1 Diabetes. Diabetes. 2016

    🔬 Clinical Development Pipeline (SAB BIOTHERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo OTHER Phase PHASE2 Type 1 Diabetes ClinicalTrials.gov
    Low Dose SAB-142 DRUG Phase PHASE2 Type 1 Diabetes ClinicalTrials.gov
    High Dose SAB-142 DRUG Phase PHASE2 Type 1 Diabetes ClinicalTrials.gov
    Single Ascending Dose of Placebo DRUG Phase PHASE1 PHA1A ClinicalTrials.gov
    Single Ascending Dose of SAB-176 DRUG Phase PHASE1 PHA1A ClinicalTrials.gov
    SAB-176 BIOLOGICAL Phase PHASE2 Influenza A H1N1 ClinicalTrials.gov
    Normal Saline OTHER Phase PHASE1 Influenza Type A ClinicalTrials.gov
    SAB-185 BIOLOGICAL Phase PHASE1 COVID-19 ClinicalTrials.gov
    Normal (9%) Saline OTHER Phase PHASE1 Middle East Respiratory Syndrome Coronavirus ClinicalTrials.gov
    SAB-301 BIOLOGICAL Phase PHASE1 Middle East Respiratory Syndrome Coronavirus ClinicalTrials.gov

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: SAB BIOTHERAPEUTICS, INC.
    • Ticker Symbol: SABS

Search

News categories